ANVS News and Press, Annovis Bio Inc. From 06/05/24

Annovis Bio (NYSE: ANVS) , a late-stage, clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”) will host an investor webcast. Accordin...

MALVERN, Pa., June 05, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’...

MALVERN, Pa., May 21, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced the publication of a new article focused on the compa...

2024-05-17 06:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-15 10:01:12 ET More on Health Care Select Sector SPDR XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care Health care is still very crowded but trades at a discount vs. history - BofA Health ca...

2024-05-13 13:07:36 ET More on GameStop: GameStop: Approaching An Optimistic Fair Value But Not There Yet GameStop: Operations Are Stabilizing, But Expect More Pain To Come GameStop: Compelling Risk To Reward Profile Ahead Of Q4 Earnings GameStop's sudden mem...

2024-05-13 07:59:02 ET More on Annovis Bio Annovis Bio: Alzheimer's Disease Topline Data Disappoints The Market Impact Of Buntanetap Trial Results On Annovis Bio Stock And Future Prospects Annovis Bio: Alzheimer's Phase 2/3 Topline Readout Puts Future For Buntanetap ...

MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, provided updates from across the organization and announced fir...

2024-05-09 20:43:22 ET Summary Recent results suggest that buntanetap, along with other treatments, does not significantly improve the condition of moderate Alzheimer's disease patients. Many current drug candidates for Alzheimer's disease work too far upstream in the disease proc...

2024-05-09 15:34:49 ET Annovis Bio ( NYSE: ANVS ) shares traded higher Thursday after the biotech said that initial data from a Phase 3 trial for its lead candidate buntanetap in early Parkinson’s disease is now expected in June.... Read the full article on Seeking Alph...